Abstract:1084 Objectives To develop PIB and THK523 based molecular probe for imaging in vivo both amyloid deposits and NFTs. Methods Standard reference THKP and precursor TKP were designed and synthesized. [18F]-TKP was automatically synthesized using one pot and two-pot reaction. Labelling yields, synthesis time and the specific activity of [18F]-TKP were compared. Biodistribution in brains were evaluated. Results The radiochemical purity of [18F]-TKP was greater than 95%. The radiolabelling yield of [18F]-TKP was obtained in a range of 18 ± 3% (n=6, one pot) and 25 ± 5% (n=6, two-pot). The total synthesis time of [18F]-TKP were 45-55 min and 55-70 min and the specific activities were 0.7 ± 0.2 Ci/µmol and 1.5 ± 0.2 Ci/µmol at the end of synthesis for one pot and two pot reaction, respectively (decay corrected to EOB). Biodistribution of [18F]-TKP displayed high brain permeability at early time point. At later points, [18F]-TKP was cleared rapidly from wild-type rat brains, indicating low non-specific binding in vivo. Small molecular probe [18F]-TKP has been developed that readily entered the brain. Conclusions In summary, we reported here the design, synthesis, and evaluation of a novel imaging probe [18F]-TKP based on the major component of THK523 and PIB. [18F]-TKP can be labeled with 18F by using one-pot and two-pot reaction. The two-pot reaction is preferred because the high yield and specific activity can be achieved. In addition, in vivo microPET study of [18F]-TKP in normal rats showed a good initial brain penetration and rapid washout from the brain. These studies suggested that [18F]-TKP could be easily performed on an automated synthesis module for routine production of high yield and might be a useful PET radiotracer for AD imaging but awaits further evaluation in animal models of AD disease. Research Support National Natural Science Foundation of China (Nos. 81271516 and 81371625), Program of Shanghai Science and Technology Commission (Nos. 13JC1401503 and 14DZ1930402), Fudan University and Shanghai Municipal Health and Family Planning Commission (Project No: 2013313).

Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2)

Radiosynthesis and Evaluation of 4-(6-[18f]fluoro-4-(5-isopropoxy-1h-indazol-3-yl)pyridin-2-yl)morpholine As a Novel Radiotracer Candidate Targeting Leucine-Rich Repeat Kinase 2.

18F-Labelled pyrrolopyrimidines reveal brain leucine-rich repeat kinase 2 expression implicated in Parkinson’s disease

Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson’s Disease

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

International Consensus on Clinical Use of Presynaptic Dopaminergic Positron Emission Tomography Imaging in Parkinsonism.

Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies

Development and evaluation of novel PET tracers for imaging cannabinoid receptor type 2 in brain

Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1

Development of a Candidate 11C-Labeled Selective Phosphodiesterase 1 Radioligand for Positron Emission Tomography

Synthesis and Radiolabelling of A Radiofluorinated Pet Imaging Probe Based on Pib and Thk523

Development of Pyridothiophene Compounds for PET Imaging of α‐Synuclein

Design, synthesis, and preclinical evaluation of 11C/18F-labeled inhibitors for RIPK1 PET imaging

Synthesis and Evaluation of a Novel PET Radioligand for Imaging Glutaminyl Cyclase Activity as a Biomarker for Detecting Alzheimer's Disease

Preclinical Evaluation of Dihydropyrazole-Cored Positron Emission Tomography (PET) Ligands for Imaging of Receptor-Interacting Serine/Threonine Protein Kinase 1 (RIPK1) in the Brain

Changes of Dopamine Transporter Detected by 11C-CFT PET in LRRK2-knockoutand G2019 Transgenicmice

Discovery and Evaluation of Imidazo[2,1- b][1,3,4]thiadiazole Derivatives as New Candidates for α-Synuclein PET Imaging

Development of a New Positron Emission Tomography Imaging Radioligand Targeting RIPK1 in the Brain and Characterization in Alzheimer's Disease

Development of a PET Probe Targeting Bromodomain and Extra-Terminal Proteins for In Vitro and In Vivo Visualization

Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson's Disease

Advances in the Use of Positronic Radiomolecular Imaging Agents in the Diagnosis of Parkinson's Disease